iLite CD3 Effector Assay Ready Cells

$1,535.00

The Eagle Bioscience’s iLite CD3 Effector Assay Ready Cells can be used for the assessment of CD3-mediated T-cell activation and for the quantification of bispecific anti-CD3-CD19 activity. The iLite CD3 Effector Assay Ready Cells can be used together with iLite CD19 Target Assay Ready Cells for quantification of bi-specific antibody Blinatumomab activity. The iLite CD3 Effector Assay Ready Cells are for research use only and not to be used for diagnostic procedures.

iLite CD3 Effector Assay Ready Cells

iLite CD3 Effector Assay Ready Cells are Developed and Manufactured by Svar Life Science

The Eagle Bioscience’s iLite CD3 Effector Assay Ready Cells are intended for the:

  • Assessment of CD3-mediated T-cell activation.
  • Quantification of bispecific anti-CD3-CD19 activity.

The iLite CD3 Effector Assay Ready Cells can be used together with iLite CD19 Target Assay Ready Cells for quantification of bi-specific antibody Blinatumomab activity.

Content: >250 μL of iLite Assay Ready Cells suspended in cryoprotective medium from Gibco.

Receipt and Storage: Upon receipt confirm that adequate dry-ice is present, and the cells are frozen. Immediately transfer to -80°C storage. Cells should be stored at -80°C or at lower temperature and are stable as supplied until the expiry date shown. Cells should be diluted and plated immediately after thawing.

For Research Use Only


Key Benefits of iLite Assays

  • Highly specific reporter gene cell lines
  • Very sensitive cell line responses (10 fold inductions)
  • Assay Ready Cells – ready-to-use from the freezer, without culturing of cells
  • Assays within a workday (typically 4-7 hour assays)
  • Normalization gene, which eliminates unwanted matrix effects

Product Description

The iLite CD3 Effector Assay Ready Cells are human-engineered cells. The CD3 Effector Assay Ready cells can be used alone or in combination with a target cell to measure a biological response when the NFAT pathway is induced by activation of the CD3 receptor on the effector cell, resulting in the reporter luciferase expression.


Related Products

iLite IL-2 Assay Ready Cells
iLite C5a Assay Ready Cells
iLite FGF-21 Assay Ready Cells

Documents

Product Manual


Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Additional Information

Background


CD3 is a complex of proteins on the surface of T cells. It is involved in activating both cytotoxic T cell (CD8+ naïve T cells) and T helper cells (CD4+ naïve T cells). T cells play a major role in many diseases such as cancer and autoimmunity and a variety of immunotherapy strategies have been used in order to target T cells/T cell subsets by inducing physiological responses, inhibiting pathogenic responses or by genetically engineering T cells (1). Several monoclonal therapeutic antibodies have been used in the clinic to inhibit tumor progression or to inhibit autoimmunity. Recently, bispecific antibodies (BsAbs) have been used in order to re-direct
immune cells to the tumors by binding to the CD3 T cell and to the tumor cell simultaneously (2). The bispecific T cell engager Blinatumomab, directed against CD19 on B cells and CD3 on T cells, received FDA approval for the treatment of B cell malignancies in 2014 (1).

Discover the Benefits of iLite®


Frequently Asked Questions

Frequently Asked Questions


Product Citations